Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injec...
Hlavní autoři: | Borchert, GA, Kiire, CA, Stone, NM, Akil, H, Gkika, T, Fischer, MD, Xue, K, Cehajic-Kapetanovic, J, MacLaren, RE, Charbel Issa, P, Downes, SM, De Silva, SR |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Springer Nature [academic journals on nature.com]
2024
|
Podobné jednotky
-
Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
Autor: Borchert, GA, a další
Vydáno: (2024) -
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Autor: Helene O. Larsen, a další
Vydáno: (2023-07-01) -
Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema.
Autor: Waldstein, S, a další
Vydáno: (2012) -
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Autor: Lorenzo Ferro Desideri, a další
Vydáno: (2023-05-01) -
Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Autor: Hang A, a další
Vydáno: (2024-12-01)